| Value | ₹1,069 Cr |
|---|---|
| Execution period | Before end of July 2026 |
NSE filing, NSE: NATCOPHARM. Summary written from the filing by ALFA Finder's alert engine.
Natco Pharma Ltd: key numbers
- Share price
- ₹793.00
- Market cap
- ₹15,556 Cr
- Revenue (annual)
- ₹4,078 Cr
- Net profit (annual)
- ₹1,418 Cr
- P/E (TTM)
- 13.6×Sector 46.1×
- Promoter holding
- 49.39%-0.03% QoQ
- FII holding
- 15.99%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Natco Pharma Ltd
All →Natco Pharma Capital Structure Change
Natco Pharma's ₹1,279.4 Crore rights issue closed on October 22, 2026. Shares were priced at ₹750 each on a ₹2 face value.
- Value
- ₹1,279 Cr
Natco Pharma Product Launch
Natco Pharma launches Carboplatin Injection, a Paraplatin® generic, in the U.S. market via its subsidiary. The oncology product addresses a critical U.S. supply shortage.
Natco Pharma Other Announcement
Natco Pharma Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory compliance submission.
Natco Pharma Share Pledge
Promoter V.C. Nannapaneni pledged 850,000 shares of Natco Pharma, valued at ₹67.10 Crore. This pledge creation increases encumbrance on promoter shareholding.
- Value
- ₹67.10 Cr
Natco Pharma Fund Raise of ₹2,000 Cr
Natco Pharma shareholders approved fund raising of up to Rs. 2,000 Crore through various instruments, along with other routine AGM resolutions.
- Value
- ₹2,000 Cr
Natco Pharma Annual General Meeting
Natco Pharma held its 43rd Annual General Meeting on September 30, 2026. Shareholders approved all agenda items, including a fund-raising authorisation limit of Rs. 2,000 Crore.
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.